Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients

Cancer Research

Volumn 52, Issue 21, 1992, Pages 6101-6105

  Foekens, John A ^a   Schmitt, Manfred ^b   van Putten, Wim L J ^a   Peters, Harry A ^a   Bontenbal, Marijke ^a   Janicke, Fritz ^b   Klijn, Jan G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CYTOSOL; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMAN; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0026440080     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P. I., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
2. Liotta, L. A., Thorgeirsson, U. P., and Garbisa, S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev.,; 277-297,1982.
3. Rochefort, H., Capony, F., and Garcia, M. Cathcpsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev., 9: 321-331, 1990.
4. Vassalli, J. D., Baccino, D., and Belin, D. A cellular binding site for the Mr 55,000 form of the plasminogen activator urokinase. J. Cell Biol., 100: 86-92, 1985.
5. Needham, G. K., Sherbet, G. V., Farndon, J. R., and Harris, A. L. Binding of urokinase to specific receptor sites on human breast cancer membranes. Br. J. Cancer., 55: 13-16, 1987.
6. Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V., and Garbisa, S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res., 41:4629-4636, 1981.
7. McGuire, W. L. Adjuvant treatment of node-negative breast cancer. N. Engl. J. Med., 320: 525-527, 1989.
8. Hillner, B. E., and Thomas, T. J. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N. Engl. J. Med., 324: 160-168, 1991.
9. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H. J. Urokinase plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer (Phila.), 62: 531-533, 1988.
10. Janicke, F., Schmitt, M., Hafter, R., Hollreider, A., Babic, R., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4:69-78, 1990.
11. Janicke, F., Graeff, H., and Schmitt, M. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost., 17: 303-312, 1991.
12. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., and Graeff, H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat, in press, 1992.
13. Graeff, H., Harbeck, N., Pache, L., Wilhelm, O., Janicke, F., and Schmitt, M. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis, 6 (Suppl. 4); 45-53, 1992.
14. Schmitt, M., Janicke, F., and Graeff, H. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagulation Fibrinolysis, 1:695-702, 1990.
15. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. L., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50:6827-6829, 1990.
16. Foekens, J. A., Portengen, H., van Putten, W. L. J., Trap man, A. M. A. C., Ruebi, J-C, Alexieva-Figusch, J., and Kltfn, J. G. M. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res., 49: 7002-7009, 1989.
17. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16: 1513-1515, 1980.
18. Barlow, R. E., Bartholomew, D. J., Bremner, J. M., and Brunk, H. D. Statistical Interference under Order Restrictions. London: John Wiley & Sons, Inc., 1972.
19. Foucre, D., Bouchet, C., Hacene, K., Pourreau-Schneider, N., Gentile, A., Martin, P. M., Desplaces, A., and Oglobine, J. Relationship between cathepsin D., urokinase, and plasminogen activator inhibitors in malignant vs. benign breast tumours. Br. J. Cancer, 64: 926-932, 1991.
20. Needham, G. K., Nicholson, S., Angus, B., Farndon, J. R., and Harris, A. L. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res., 48:6603-6607, 1988.